FIELD: medicine.
SUBSTANCE: group of inventions refers to versions of applying an antisecretory protein which corresponds the amino acid sequence SEQ ID NO:6, its homologue, and/or a fragment containing the amino acid sequence SEQ ID NO:4 showing equivalent activity, and/or its pharmaceutically active salt for preparing a pharmaceutical composition and/or nutritional care for treatment and/or prevention a dysfunction, e.g. a pathological function, lipid raft, receptor and/or small pit hypo- or hyperfunction. The lipid raft, receptor and/or small pit dysfunction can be induced by or cause a number of the other conditions, such as vascular and pulmonary dysfunctions and/or endocrine disorders, e.g. diabetes and related disorders.
EFFECT: group of inventions enables controlling intracellular transport and cell product release, as well as normalising tissue component distribution in various diseases.
13 cl, 12 ex
Title | Year | Author | Number |
---|---|---|---|
NEW APPROACH TO TREATMENT OF COMPARTMENT - SYNDROME | 2007 |
|
RU2465914C2 |
METHOD FOR PRODUCTION OF EGG YOLK WITH HIGH CONTENT OF AF-16 | 2016 |
|
RU2723097C1 |
NEW THERAPEUTIC APPROACH TO INTRAOCULAR PRESSURE INCREASE | 2007 |
|
RU2458703C2 |
NEW APPLICATION | 2004 |
|
RU2416426C2 |
NEUROENDOCRINE FACTORS FOR TREATING DEGENERATIVE DISORDERS | 2008 |
|
RU2496790C2 |
UROCORTIN-III, ITS ANALOG (VARIANTS) AND PHARMACEUTICAL COMPOSITION | 2002 |
|
RU2305109C2 |
APOPTOSIS INHIBITORS AND USE THEREOF | 2011 |
|
RU2582247C2 |
TRANSDUCIBLE POLYPEPTIDES FOR MITOCHONDRIAL METABOLISM MODIFICATION | 2009 |
|
RU2529950C2 |
PURIFIED IMMUNOGENIC PROTEIN, ITS FRAGMENTS AND DERIVATIVES | 1999 |
|
RU2304585C2 |
MUTANT POLYPEPTIDES SUAA AND POLYPEPTIDE DERIVATIVES SUITABLE FOR DELIVERY OF IMMUNOGENIC MOLECULES IN CELL | 2010 |
|
RU2585216C2 |
Authors
Dates
2012-08-10—Published
2007-04-27—Filed